A Phase 3, Open-Label, Single-Arm, Multicenter Study to Evaluate Ravulizumab Administered Intravenously in Pediatric Patients With Anti-Acetylcholine Receptor Antibody-Positive (AChR-Ab+) Generalized Myasthenia Gravis (gMG) (P7-6.014)
Characterize the pharmacokinetics (PK), pharmacodynamics (PD), efficacy, safety, and immunogenicity of intravenous ravulizumab in pediatric patients with anti-acetylcholine receptor antibody-positive (AChR-Ab+) generalized myasthenia gravis (gMG).
Authors
- Sarbesh Pandeya (ORCID: https://orcid.org/0000-0002-2875-8425)
- Gwendolyn Niebler
- S. Chakravarty (ORCID: https://orcid.org/0000-0002-3682-2060)
- Glen Frick
Institutions
- AstraZeneca (Brazil) (BR)
- Alexion Pharma (Switzerland) (CH)
Publication Details
- Journal
- Neurology
- Published
- 2025-04-07
- DOI
- https://doi.org/10.1212/wnl.0000000000208761
- Primary Topic
- Myasthenia Gravis and Thymoma
- Type
- article
- Field-Weighted Citation Impact
- 0.00